ASCOT supports superiority of newer over older antihypertensive drug by Birkenhäger, WH & Staessen, Jan A
 1
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  ss 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      
Dear ISH member, 
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TO:  Members of the International Society of Hypertension 
  
We should like to inform you that the ISH has a new Secretariat.  All 
enquiries regarding your membership and other aspects of the Society 
should be addressed as follows: 
  
ISH Secretariat, 
Hampton Medical Conferences Ltd., 113-119 High Street, Hampton Hill,  
Middlesex, TW12 1NJ, U.K. 
  
Tel:  +44 (0) 20 8979 8300                    Fax: +44 (0) 20 8979 6700 
Email:  secretariat@ish-world.com        Web:   www.ish-world.com 
  
Please visit the ISH’s newly launched website:   
www.ish-world.com 
 
  
Any opinions expressed in the email are those of the individual and not necessarily of the Society. This email and any files transmitted 
with it are confidential and solely for the use of the intended recipient to whom they are addressed. If you are not the intended recipient 
or the person responsible for delivering to the intended recipient, be advised. 
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In this issue, Opus 8, you will find: 
 
1. A report from the ISH president, Professor M Alderman, pp 3-4 
2. A presentation of the new ISH agent, Hampton Medical Conferences, pp 5-6 
3. Invited comments on ASCOT by Professors W Birkenhäger, J Staessen, and J 
Chalmers, pp 7-11 
4. A report from the Editor of the J Hypertension, Professor A Zanchetti, pp 12-14 
5. A contribution from the Israeli Society of Hypertension by Professor E 
Grossman, pp 15-16 
6. A short report from the recent ESH meeting in Milan by Professor G Mancia,  
p 17 
7. Information on “How to become an ISH member”, pp 18-19 
 
As shown on page 1, ISH now has a new website. As soon as we get the updated 
membership list in order, we will add more information on the website available for 
paying ISH members only. The access code will be sent out later this year or early 
next year from our Secretariat. Those who have not paid the fees for the last two years 
or longer are at risk of being struck off the list (according to ISH By-Laws, Article 
III:7.0).  
 
Finally, thanks for all your comments and encouraging remarks which we received 
before summer. It is fantastic that several hundred ISH members responded within a 
few days when we sent out a questionnaire attached to Opus 7. The overall 
assessment [mean (SD), 5=best, 1=worst] was a favourable 4.0 (0.7) and members 
found the newsletter easy to open, 4.3 (0.8) and of an appropriate size, 3.7 (1.0). 
 
Please recruit new members! 
 
Enjoy, 
 
Lars H Lindholm 
Editor of ISH News 
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REPORT FROM THE PRESIDENT 
MH Alderman 
New York, U.S.A. 
 
The 2005 ISH Scientific Council met in conjunction with the European Society of 
Hypertension Scientific Session in Milan in mid-June. Attendance was excellent, 
although bureaucratic misadventure kept two members away. The meeting provided 
the setting for two important transitions. First was the election of Professor Lars H 
Lindholm as the next President of ISH. 
 
Lars has served the Society with diligence and distinction since joining its Scientific 
Council in 2000. For the past two years he has been an active member of its 
Executive Committee, and also edited the highly successful ISH Newsletter. Lars is 
also widely respected for distinguished leadership of many major international trials of 
antihypertensive therapy, as well as for careful analysis of controversial issues in 
antihypertensive therapy. His widely respected editorial commentaries appear 
frequently in leading international medical journals. In sum, Lars H Lindholm is 
uniquely well suited to provide creative and effective leadership for our increasingly 
active society. 
 
Professor Lars H Lindholm will serve as President-Elect before assuming the 
Presidency at the conclusion of the 21st Scientific Meeting in Fukuoka, Japan, 
October 15–19, 2006.  
 
The Scientific Council Meeting also marked transfer of administrative responsibility 
from the very capable hands of Ms. Sue Davenport in Geneva to the Hampton Medical 
Conference Group in London. Under the direction of Ms. Jacinta Scanell and Elaine 
Oliver, the transition has been elegantly accomplished. A more detailed description of 
their exciting plans for the future, including the launch of a new website, are detailed 
elsewhere in this issue.  
 
The Scientific Council also received encouraging reports on progress for the two up-
coming Scientific Meetings in Fukuoka (2006) and Berlin (2008). Professors Ogihara, 
a current member of the Scientific Council, and Saruta, a past council member, have 
assembled able and effective Organizing and Program Committees. Professor Trevor 
Morgan has announced that the Asian-Pacific Society of Hypertension, of which he is 
President, will hold its 5th congress in conjunction with the Fukuoka meeting. Thus, a 
remarkable confluence of local, regional, and international support ensures a large 
turnout for what promises to be an outstanding scientific program in a most appealing 
venue. 
 
Timely state-of-the-art lectures, breakfast symposia, and late-breaking clinical trials 
have been planned. In addition, there will be nearly 100 oral as well as poster 
presentations selected from submitted abstracts. I urge all members to submit their 
best research work for presentation (abstract deadline April 15, 2006) at Fukuoka, and 
make travel plans early. 
 
On another note, former ISH President John Chalmers and Dr. Liu Leshang organized 
an ISH Faculty visit to China in August. Pavel Hamet, Simon Thom, Judith Whitworth, 
and I participated in lively symposia in Shanghai, Chendu, Wuhan, and Beijing.  
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The visit provided an opportunity for many Chinese physicians to become familiar with 
ISH, and for us to establish personal ties with a number of very able young Chinese 
investigators. The possibility of further visits to this most vibrant country, perhaps to 
coincide with the Fukuoka meeting, was discussed.  
 
At the Fukuoka meeting of the Scientific Council in 2006, new members of the 
Scientific Council will be elected. Terms are initially for four years, but generally are 
extended for an additional second term. I urge members to contact me or other 
Council Members with suggestions for suitable candidates. Formal nominations must 
be received by the summer of 2006. 
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Brief facts about HMC to date: 
• Ordered more than 500,000 cups 
of coffee! 
• Processed 54,202 delegates 
• Sold 7,079 exhibition stands and 
sponsorship packages 
• Invited 5,596 speakers 
• Managed 544 round table 
meetings 
• Organised 368 conferences 
 
Hampton Medical Conferences (HMC) Ltd 
The new ISH agent 
 
We recently appointed Hampton Medical Conferences Ltd (HMC) to provide 
secretariat services for the Society. 
 
Based in Hampton Hill, Middlesex, UK, HMC has considerable experience of 
association management, having been retained by a number of medical societies to 
provide a complete administrative service. They specialize in the organization of 
medical symposia, offering a service to academic societies and associations, 
individual physicians and the pharmaceutical industry. The company is already familiar 
with the work of the ISH having being responsible for the Scientific Secretariat for the 
16th Scientific Meeting of the International Society of Hypertension in 1996 in 
Glasgow, UK. For this meeting they handled over 2,300 abstract submissions, 500 
referees, 400 speakers and chairmen, 1,200 poster presentations, 3 different 
awards/travel grants linked to abstract submission and 5 Conference Sub-
Committees. 
Their clients include UK and international medical societies and associations, 
pharmaceutical companies and individual physicians with innovative meeting ideas. 
HMC was formed in June 1988 and now has 20 
permanent staff, together with a regular team of 
freelance conference staff, who organize events 
throughout the UK, Europe and worldwide. They offer a 
complete range of services associated with conference 
and exhibition management and secretariat services. 
Their bespoke delegate management systems will be 
tailored to meet the specific needs of the ISH, including a 
secure online payment and membership renewal system. 
 
The team at HMC have already developed a new website for the ISH and we urge you 
to log on and visit us at www.ish-world.com. Further developments are planned 
including a secure membership area where you will be able to read the newsletter in 
due course. 
 
If you wish to correspond with the new secretariat, please contact them at: 
 
ISH Secretariat, c/o Hampton Medical Conferences Ltd, 113-119 High Street, 
Hampton Hill, Middlesex TW12 1NJ, U.K. 
Tel: +44 (0) 20 8979 8300  Fax: +44 (0) 20 8979 6700 
Email: secretariat@ish-world.com  www.ish-world.com 
 
Directors of Hampton Medical 
The Joint Managing Directors, Elaine Oliver and Jacinta Scannell, are both fully 
elected members of the Association of British Professional Conference Organisers 
(ABPCO) and agree to abide by the Code of Practice laid down by the Association. 
Both Elaine and Jacinta will be working closely with the Executive Committee and 
Council to manage the Society. 
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Elaine Oliver 
Elaine Oliver has 12 years experience of organizing medical conferences both at the 
British Medical Association and at Hampton Medical Conferences. Events range from 
intimate workshop-style meetings to international congresses with up to 1500 
delegates; her experience includes the organization of associated exhibitions and 
social events. Elaine was appointed as Joint Managing Director in February 2002 
since when she has managed this progressive company. 
 
 
 
 
Jacinta Scannell 
Jacinta Scannell has worked in administration for over 20 years. Her early career was 
in industry but since moving to London in 1989, she has worked in conference 
management. As the senior administrator and conference organizer for a professional 
academic association for 10 years Jacinta developed a very solid understanding of 
committee administration. She was also responsible for ensuring that the organization 
fulfilled its constitutional and statutory requirements under rule. As Joint Managing 
Director at HMC, she shares responsibility for business development, staffing, and all 
event management. 
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For this issue of HT News we invited Prpfessors W. Birkenhäger, J Staessen, and J 
Chalmers to give their comments on the ASCOT results. We also invited the 
two first authors of the recent Lancet publications, Professor Neil Poulter and  
Doctor Björn Dahlöf, to respond which, however, they declined to do in order to “keep 
their powder dry pending the Lancet correspondence columns”. 
 
Lars H Lindholm 
Editor, ISH News 
 
ASCOT supports superiority of newer over older antihypertensive 
drugs 
W. H. Birkenhäger 
Rotterdam, The Netherlands 
Jan A. Staessen 
Leuven, Belgium 
 
This is another important milestone in the series of prospective randomized 
comparative hypertension trials. 
As in previous trials of this class (VALUE etc.) study subjects were selected on the 
basis of hypertension plus one or several additional CV risk factors. This is quite 
appropriate from an ethical point of view; moreover, this choice facilitates the 
evaluation of the outcome in a relatively short period, given the unwritten but generally 
recognized law that the greater the initial risk, the better the chance of attaining 
significant differences between randomized group outcomes. This obviously reduces 
the time scale of a trial. On the other hand, these tactics imply that the results 
(differences in outcome) need not necessarily by applicable to uncomplicated “middle 
of the road” hypertensives as seen in daily practice. 
It is argued that the “ancient” combination of a beta-blocker and a thiazide diuretic, 
despite their complementary beneficial effects on blood pressure as such, shares 
common disadvantages of potentially harming the metabolic status of patients so 
treated. Such unwanted effects as the new onset of diabetes and dyslipidaemia (in the 
meantime recognized as components of the metabolic syndrome in substantial 
numbers of hypertensives) may well neutralize any favourable effect on blood 
pressure per se. 
By contrast, the newer antihypertensive agents, such as the dihydropyridine class of 
calcium channel blockers, ACE inhibitors, and AT1-blockers are apparently devoid of 
such potentially ominous effects. The pharmaceutical industry, for obvious reasons, 
has shown to be keen on carrying the message one step further, by claiming that the 
new antihypertensive agents (with accents on their trade marks!) may even harbour 
the potential of improving cardiovascular status over and above their ability to achieve 
blood pressure control! In our perception this venture is one bridge too far, in general 
terms of explaining such favourable outcomes. 
Back in 2001 one of us (J.A.S. et al) introduced another interpretation through a 
“meta-regression” analysis of blood pressure differences and demonstrated that 
differences in cardiovascular outcome between different regimens could readily be 
explained on the basis of relatively tiny gradients in systolic blood pressure.  
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This evaluation was updated in 2003. It appeared in the meantime that in such huge 
trials, as the present one, it is quite difficult, if not impossible, to achieve complete 
equivalence of average systolic blood pressure between groups assigned to different 
treatment regimes. The differences in outcome correlated well with such ostensibly 
tiny in-trial differences in systolic blood pressure. This also applies to the ASCOT trial. 
The conclusion seems justified that the newer drugs simply turn out to be better 
antihypertensives, although it still remains to be established which of the latter would 
be preferable as first-line drug. 
Furthermore, the findings do not exclude the possibility that some antihypertensive 
agents may exert specifically beneficial actions on such sensitive end organs as the 
kidney or the brain, irrespective of their effects on blood pressure. The kidneys seem 
to profit most from drugs inhibiting the renin-angiotensin system, although according to 
some studies dihydropyridine calcium channel blockers may achieve comparable 
effects. 
The main concern of our profession should extend to our single irreplaceable organ, 
the brain. Strokes as such to an appreciable extent have shown to be preventable 
through timely antihypertensive treatment. But the dementias (both Alzheimer’s 
disease and vascular dementia) loom ahead as a major (pandemic) scourge in the 
increasingly elderly population. Time and again it has been demonstrated that 
hypertension is a main (and potentially remediable) factor in the pathogenesis of both 
dementia subtypes. 
Why is it, then, that hypertension trialists apparently tended to turn a blind eye to this 
most challenging of end points and that a potential wealth of preventive information 
has gotten lost down the drain in the majority of valuable comparative trials? One can 
only speculate that it must have been due to reluctance to tread unknown paths, even 
though the placebo-controlled Syst-Eur trial, followed by the SCOPE and PROGRESS 
trials, have demonstrated the feasibility of incorporating at least such simple screening 
test as the M.M.S.E. (Mini-Mental State Examination), which upon meta-analysis 
indicated an exclusive benefit of 50–55% prevention or postponement of dementia 
based on a dihydropyridine calcium antagonist (nitrendipine). 
Despite the squandering of such essential information in the above comparative 
mega-trials, one still may be facing further opportunities for compensating for those 
lost opportunities. Given the better performance of the new drugs combination in 
ASCOT-BPLA, there will still be a need for establishing a preferential first single 
treatment agent (dihydropyridine CCB, ACE-inhibitor, AT1-blocker …) and a common 
additional drug if necessary. That would provide a golden opportunity for incorporating 
a psychometric follow-up assessment on top of the usual range of somatic evaluations 
and hence paving the way towards optimal prevention of mental deprivation in 
hypertensives. 
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ASCOT – An Anglo-Scandinavian triumph! 
John Chalmers 
Sydney, Australia 
 
What a study! Few deliver half of what their initiators dare to hope for. This one has 
turned up trumps in almost every respect, and ahead of time! – both arms of the 2x2 
factorial stopped early due to impressively positive results. 
 
The first to be stopped, ASCOT-LLA (The Lipid Lowering Arm), was halted after 3.3 
years of a planned 5-year follow-up (1). Among 10,305 hypertensive patients with a 
non-fasting total cholesterol of 6.5 mmol/l or less, only 100 patients on atorvastatin 10 
mg had a primary event (non-fatal MI and fatal CHD), compared to 154 on placebo (a 
hazard ratio of 0.64). Kaplan-Meier curves revealed separation and a trend to benefit 
from the first few months, and most secondary endpoints (total stroke, total coronary 
events, total coronary events and procedures) were reduced by between 20 and 30% 
in the group receiving atorvastatin (1). 
 
Now ASCOT-BPLA, the second, blood pressure lowering arm, has been stopped 
before reaching its target of 1150 primary events, because mortality and a majority of 
other secondary endpoints were clearly more frequent on conventional combination 
therapy (atenolol and bendroflumethiazide based therapy) than on combination 
therapy with newer drugs (amlodipine and perindopril based therapy) (2). 
 
Among 19,257 patients with moderately severe hypertension (untreated >160/90 
mmHg or treated >140/90 mmHg) and at least three other cardiovascular risk factors, 
all-cause mortality and cardiovascular mortality were reduced by 11% (p=0.025) and 
24% (P=0.001) respectively in the group assigned to the amlodipine/perindopril 
combination strategy compared to those on the atenolol/bendroflumethiazide 
combination strategy. In addition secondary endpoints such as total stroke (by 23%), 
total coronary events (by 13%), total coronary events and procedures (by 16%) were 
all significantly reduced in those on the newer agents. The risk of new onset diabetes 
was also reduced by 30% by the amlodipine/perindopril strategy. Interestingly, there 
was no significant reduction in heart failure in those on the newer agents, potentially 
revealing the negative effects of calcium antagonists in this respect, reported in other 
studies (3, 4). 
 
ASCOT-BPLA is the first trial that seeks formally to compare 2 “combinations”, one 
with 2 “newer agents” (amlodipine and perindopril) and the other with 2 “older drugs” 
(atenolol and bendroflumethiazide) but even this is really a comparison between 2 
treatment algorithms, which the authors term “treatment strategies” since overall only 
around half were actually taking each of the two nominated combinations throughout 
the trial (2). 
 
The striking benefit that the “newer agent” strategy combining amlodipine and 
perindopril conferred on most cardiovascular endpoints in ASCOT-BPLA, is difficult to 
reconcile with the singular lack of advantage detected when amlodipine and lisinopril 
were each compared head to head with chlorthalidone in ALLHAT (3).  
 
It is also difficult to reconcile the results of ASCOT-BPLA with the lack of difference in 
the risk of stroke and coronary disease between ACE inhibitors, or Calcium 
Antagonists on the one hand and “conventional” therapy on the other, reported by the 
Blood Pressure Lowering Treatment Trialists’ Collaboration (4).  
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It is not at all clear whether the cardiovascular benefits of the amlodipine/perindopril 
strategy reflect specific benefits of these two particular agents, class benefits 
associated with calcium antagonists and/or ACE inhibitors, specific negative effects of 
either atenolol or bendroflumethiazide, or negative class effects associated with beta 
blockers and/or diuretics. While many readers will tend to attribute the results to the 
beneficial effects of calcium antagonists and ACE inhibitors, a few may be tempted to 
blame atenolol, which has been found wanting elsewhere (5, 6). Thus the differences 
compared to ALLHAT could be attributed by a mischievous commentator to the 
negative effects in ASCOT-BPLA of atenolol, or even to the superior effects in 
ALLHAT of chlorthalidone (2, 3).  
 
Commentators and readers will all note that the blood pressures were lower by 2.7/1.9 
mmHg in the amlodipine/perindopril group, a difference reminiscent of the HOPE study 
(7) where an ACE inhibitor also achieved significant benefits with only a small 
difference in blood pressure. The relative contribution to the benefits seen in ASCOT-
BPLA of this blood pressure difference, particularly the 2.7 mm Hg difference in 
systolic blood pressure, and of other drug-related characteristics is already a bone of 
contention (8,9). This debate, fuelled by the back-to-back publication of the companion 
paper (8), is unfortunate, especially as the analyses presented are polluted by non-
randomized data, and as the authors themselves admit, their multivariate adjustment 
procedures are incomplete and likely to underestimate the true effects of the variables 
considered, such as the blood pressure (8). The argument detracts from the main 
conclusions to be drawn from ASCOT-BPLA, that the newer agents, amlodipine and 
perindopril are remarkably effective blood pressure lowering drugs, remarkably 
effectively in reducing cardiovascular mortality and morbidity and very effective in 
reducing the onset of newly diagnosed diabetes (2). The argument also muddies the 
main message, that the key to reducing the morbidity and mortality with these two 
agents is effective blood pressure reduction and the more the merrier!  
 
The results and the authors’ interpretation of ASCOT-BPLA plainly balance out the 
results and the authors’ interpretation of ALLHAT(3), two studies of similar weight, with 
around 10,000 participants in the various randomized treatment groups (2, 3). In one, 
the authors of ALLHAT argue that conventional treatment (the diuretic chlorthalidone) 
is superior and should constitute the preferred initial treatment, while in the other, the 
authors of ASCOT-BPLA argue that newer agents (in this case the calcium antagonist 
amlodipine and the ACE inhibitor perindopril) are superior and that conventional 
treatment with a beta blocker and a diuretic should not be preferred for routine use. 
Indeed, the ASCOT authors would restrict the use of the beta blocker/diuretic 
combination to “specific circumstances”. My own view, given the new evidence from 
ASCOT-BPLA (2), would sit between the two. I would now neither prefer nor avoid 
conventional therapy with diuretics and beta blockers, and in this respect, I would 
agree with the recommendations of the 2003 European Guidelines and indeed with 
those of the 1999 WHO-ISH Guidelines for the treatment of hypertension (10, 11).  
Both these guidelines recommend that the doctor should choose from among the 5 
classes of front-line drugs, and tailor this choice according to the clinical situation in 
the individual patient (10, 11). They also stress the importance of a combination 
therapy. This advice seems appropriate in the light of all the evidence that is currently 
available. 
 
The results of ASCOT certainly vindicate the use of newer drugs and in particular they 
re-enforce the need for combination therapy using a multiplicity of drugs in coherent 
therapeutic strategies.  
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Even in ASCOT-BPLA, the proportions of patients meeting international 
recommendations for blood pressure control were as low as one third for diabetic 
patients and less than two thirds for non-diabetic subjects (2), highlighting the 
difficulties faced by clinicians in their usual practice situations. 
 
While cost factors must most certainly be taken into account in all nations, whether 
high, middle or low income, the overwhelming public health message must continue to 
be to “lower blood pressure more stringently to meet target blood pressures, using 
rational combinations of all the drugs available in your health system, in order to 
reduce the risk of fatal and non-fatal heart attack, stroke and heart failure”. It is also 
tempting to add a rider that in subjects with diabetes, or at risk of developing diabetes 
such as those who are overweight, an inhibitor of the renin-angiotensin system should 
be included. 
 
Most good clinical trials throw up many new questions as well as answers, and 
ASCOT is no exception. But ASCOT is quite exceptional in answering most of the 
main questions that it was designed to address, in both ASCOT-LLA (1) and ASCOT-
BPLA (2). Congratulations and plaudits to all involved. 
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Report from the Editor of the Journal of Hypertension 
A Zanchetti 
Milan, Italy 
 
The Journal of Hypertension: Citations and Impact Factor 
 
The members of the International Society of Hypertension are naturally quite 
interested in the official journal of their Society, and have certainly been excited to 
learn a few months ago that the impact factor of the Journal of Hypertension has risen 
to 4.871, with a considerable further increase over the continuing trend to increased 
attention in previous years. 
 
Obviously, the impact factor has limitations: although it gives a satisfactory 
assessment of the impact the journal is having on scientific information, it does not 
provide editors and authors with a lead to which articles are receiving the greatest 
interest from their fellow scientists. Knowing the number of citations for individual 
papers and types of paper can be of undoubted interest, however. Therefore, I have 
tried to provide ISH members with some information about the citations through which 
the flattering impact factor of the Journal of Hypertension has been achieved. 
 
With the valuable help of Mrs Mara Bernardinello, librarian of the Istituto Auxologico 
Italiano, Milan, I am now able to present some summary information on the Journal of 
Hypertension articles published in 2002 and 2003 that have been more frequently 
cited in the period until 31 Dec 2004. 
 
Because of the time delay between publication of an article and its citation by other 
published articles, we have searched the ISI Web of Science for citations of papers 
appearing in the Journal of Hypertension during the year 2002 (volume 20) and, 
separately, during the year 2003 (volume 21). 
 
Among papers published in 2002, 72 had received at least 10 citations in peer-
reviewed journals by December 2004. Of these, 13 were reviews, meta-analyses, 
guidelines, editorial commentaries, but as many as 59 were original papers. Fifteen 
articles (6 reviews or editorials) had received 20 or more citations. These are listed 
below. 
 
1. Lindholm LH et al. Risk of new-onset diabetes in the LIFE study. 2002; 20: 1877. 
2. Simon A et al. Intima-media thickness: a new tool for diagnosis and treatment of 
cardiovascular risk. 2002; 20: 159 (Review) 
3. Mark AL et al. Selective leptin resistance. 2002; 20: 1245 (Review) 
4. Zanchetti A, Ruilope LM. Antihypertensive treatment in patients with type 2 
diabetes mellitus. 2002; 20: 2099 (Review) 
5. Gorzelniak K et al. Hormonal regulation of the human adipose-tissue renin-
angiotensin system: relation to obesity and hypertension. 2002; 20: 965. 
6. Fagard RH et al. Survey on the treatment of hypertension and implementation of 
WHO/ISH risk stratification in primary care in Belgium. 2002; 20: 1297. 
7. Gasowski J et al. Pulsatile blood pressure component as predictor of mortality in 
hypertension. 2002; 20: 145 (Meta-analysis) 
8. Ohkubo T et al. Prognostic significance of the nocturnal decline in blood pressure: 
the Ohasama study. 2002; 20: 2183. 
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9. Cuspidi C et al. The role of echocardiography and carotid ultrasonography in 
stratifying risk in patients with essential hypertension: the APROS study. 2002; 
20: 1307. 
10. Redon J, William B. Microalbuminuria in essential hypertension: redefining the 
threshold. 2002; 20: 353 (Editorial commentary) 
11. Schiffrin E et al. Effect of crossing over from a beta-blocker to an angiotensin-
receptor antagonist on resistance artery structure and on endothelial function. 
2002; 20: 71. 
12. Wachtell K et al. Microalbuminuria in hypertensive patients with 
electrocardiographic LHV: the LIFE study. 2002; 20: 405. 
13. Dahlof B et al. Effects of losartan and atenolol on left ventricular mass and 
neurohormonal profile in hypertensives with LVH. 2002; 20: 1855. 
14. Ferrari P et al. Additive antiproteinuric effect of combined ACE inhibition and 
angiotensin II receptor blockade. 2002; 20: 125. 
15. Mancia G, Grassi G. Systolic and diastolic blood pressure control in 
antihypertensive drug trials. 2002; 20: 1461 (Editorial). 
 
Because of the shorter time elapsed since publication, a lower number of articles 
published in volume 21 (2003) have received a conspicuous number of citations. 18 
articles (of which 8 guidelines and reviews) have received at least 10 citations, with 
the top six papers having received at least 20 citations (and the ESH/ESC guidelines 
more than 250). 
 
1.     Guideline committee. 2003 ESH-ESC guidelines for the management of       
hypertension. 2003; 21: 1011 (Guidelines) 
2. Writing group. 2003 WHO-ISH statement on hypertension management. 2003; 
21: 1977 (Guidelines) 
3. Lithell H et al. The SCOPE trial. Principal results. 2003; 21: 875. 
4. O'Brien E et al. ESH recommendations for conventional ambulatory and home 
blood pressure measurement. 2003; 21: 821 (Guidelines) 
5. Staessen J et al. Cardiovascular prevention and blood pressure reduction: a 
quantitative overview updated until 1 March 2003. 2003; 21: 1055 (Meta-analysis) 
6. Asia Pacific Cohort Studies Collaboration. Blood pressure and cardiovascular 
disease in the Asia-Pacific region. 2003: 21: 707 (Meta-analysis) 
7. Lindholm LH et al. Metabolic outcome in newly detected hypertensives. The 
ALPINE study. 2003; 21: 1563. 
8. Davies JI et al. Peripheral blood pressure measurement is as good as applanation 
tonometry at predicting ascending aortic blood pressure. 2003; 21: 571. 
9. Hope DA et al. Use of arterial transfer function. 2003; 21: 1299. 
10. ISH Writing Group. 2003 ISH statement on blood pressure lowering and stroke 
prevention. 2003; 21: 651 (Guidelines) 
11. Lin Y et al. Central cardiovascular action of urotensin II in conscious rats. 2003; 
21: 159. 
12. Davies BJ et al. Disparate effects of ARBs and CCBs on albuminuria in 
experimental diabetes. 2003; 21: 209. 
13. Aronson D. Cross-linking of glycated collagen in arterial and myocardial stiffening 
of aging and diabetes. 2003; 21: 3 (Review). 
14. ISH Writing Group. 2003 ISH statement on the management of blood pressure in 
acute stroke. 2003, 21: 665 (Guidelines). 
15. Vonend O et al. Moxonidine in renal failure. 2003; 21: 1709. 
16. Grassi G et al. The CROSS study. 2003; 21: 1761. 
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17. Brand E et al. Blood pressure and metabolic phenotypes in relation to the G 3 
C825T polymorphism. 2003; 21: 729. 
18. Wang X. Adrenomedullin in LVH of severely hypertensive rats: effects of ACEI 
and diuretic. 2003; 21: 1171. 
 
On the whole, although guidelines and reviews do more easily receive citations, a 
conspicuous number of citations also concern many original papers, clinical and 
experimental. Giving consideration to the preferences of the readers (web-users, see 
information on Opus no. 6) and to the slightly different ones of investigators (those 
citing papers relevant to their work), may help the readers in finding the most 
interesting information in our Journal, prospective authors in deciding which of their 
papers is most suitable for our Journal, and the editors in trying to make the Journal of 
Hypertension even more stimulating for the readers and widely cited in the medical 
literature. 
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Israeli Society of Hypertension – 2004-2005  
E. Grossman 
Tel-Hashomer, Israel 
 
High blood pressure is a major health concern in Israel as it is in the other countries of 
the European Society of Hypertension. The Israeli Society of Hypertension  includes 
more than 400 physicians who work in various fields of medicine such as general 
practice, internal medicine, cardiology, nephrology, endocrinology, epidemiology, 
research etc. The executive board includes the president, secretary, treasurer, ex-
president and two members. Elections take place every two years. The Israeli Society 
of Hypertension carried out actions to increase the awareness and to implement the 
recent guidelines to diagnose and treat hypertension among the Israeli population. 
The Israeli Society of Hypertension works to increase awareness among the 
population and put emphasis on clinical education of family physician and interaction 
with other medical societies such as Cardiology, Diabetes and Nephrology. The Israeli 
Society of Hypertension believes that since most hypertension patients have additional 
co-morbid conditions, an integrative approach and dialogue with other professional 
associations is mandatory. 
 
Epidemiology 
Physicians who work for the main HMOs in Israel use an electronic medical record, 
which sends data sets to the HMO central computer. It has therefore been possible to 
build a hypertension registry. This registry is automatically updated every month and 
is displayed on-line. Analysis of the data of one and a half million subjects who are 
older than 18 years showed that the prevalence of diagnosed hypertension in Israel is 
about 18%. However, about 40% of the subjects don’t have blood pressure 
measurements during the last 2 years in their records. Among 189,737 patients in 
Maccabi Healthcare Services who had a diagnosis of hypertension 51% had 
satisfactory blood pressure control with recorded blood pressure levels below 140/90 
mm Hg. 
 
In a survey conducted by the Israeli Society of Hypertension during the last year the 
patterns of drug treatment among primary care physicians were evaluated. We found 
that almost 70% of the hypertensive patients have, in addition to hypertension, 3 
cardiovascular risk factors or diabetes mellitus. These findings imply that most 
hypertensive patients are high-risk patients and should be treated aggressively to 
control other cardiovascular risk factors. In this survey we found that beta blockers 
and ACE inhibitors were the leading antihypertensive agents and were given to 26.1% 
and 25.4% of the patients respectively. Calcium antagonists and diuretics were given 
to 21.2% and 18.3% of the patients respectively. Angiotensin receptor blockers 
(ARBs) were given to only 3.4% of the patients. The low use of ARBs may reflect the 
limit imposed by the government on the use of expensive antihypertensive agents. 
Recently, the Israeli Society of Hypertension did a survey to calculate the 10-year risk 
of developing stroke in 1300 elderly hypertensive patients. Preliminary analysis shows 
that the calculated 10-year risk of stroke in elderly hypertensive patients is higher than 
the calculated risk of myocardial infarction, and that most physicians underestimate 
the risk of stroke in elderly hypertensive patients. The  Israeli Society of Hypertension 
in collaboration with the Ministry of Health is running now a study in 1500 elderly 
subjects around the country to assess the rate of hypertension and co-morbidities and 
the awareness and rate of blood pressure control in this population.  
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Education 
The Israeli Society of Hypertension published guidelines for the diagnosis and 
treatment of hypertension early 2004. This guidelines reflect the principles of the 
European Society of Hypertension (ESH) guidelines and modified them to the Israeli 
population and health system. Integrative guidelines for a global risk reduction in the 
patient with multiple risk factors have been completed and are about to be published.  
 
A clinical education programme was initiated last year. A monthly meeting of family 
physicians and hypertension specialists is taking place, during which an update 
seminar and clinical case management are reviewed with active participation of the 
audience and commentary by the specialists.  
 
The Third Hypertension School took place this year. Physicians after their 
specialization, primarily in internal medicine, cardiology, nephrology, endocrinology 
and family medicine, who wish to broaden their knowledge in the field of hypertension 
are the audience of this programme. Both theoretical and practical aspects of 
hypertension are discussed. 
 
The  Israeli Society of Hypertension sponsored young investigators to participate in 
international meetings. In addition the Israeli Society of Hypertension encourages 
young physicians to participate in the European educational programmes, such as the 
summer hypertension school and the advanced hypertension school. Last year two 
Israeli members participated in the summer hypertension school and one physician 
participated in the advanced hypertension school.  
 
The Israeli Society of Hypertension established a 2-year programme of fellowship in 
hypertension for physicians who are specialist in internal medicine or family medicine. 
The program includes clinical work in a recognized hypertension clinic and clinical and 
basic research in hypertension. We now have two fellows who have started this 
programme.  
 
The Israeli Society of Hypertension has a website, www.ISH.org.il, where all the 
activities are listed. The website has an update section where the recent literature is 
reviewed every month, and a Q&A section where physicians and the general 
population can ask questions and give answers. In addition, the Israeli Society of 
Hypertension distributes a monthly electronic paper to all the members. 
 
Meetings 
The Israeli Society of Hypertension has organized two annual meetings. Both state-of-
the-art lectures as well as clinical and basic research are presented.  
 
Research 
The Israeli Society of Hypertension supports basic and clinical research through 
research grants. 
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HT News Opus 8 
G. Mancia  
Monza, Italy 
 
The Fifteenth Meeting of the European Society of Hypertension has been held in Milan 
from June 17–21, 2005. The meeting was an outstanding success because of the 
large attendance and the high quality of the highly diversified scientific programme. 
About 6,500 clinicians and investigators from all European and many non-European 
countries participated in the scientific sessions which accommodated 186 oral 
presentations, 10 lectures, 2 debates and 1161 posters. In addition many sessions 
were pre-structured (Topical Workshops) to address issues of current interest dealt 
with by worldwide experts. Specific treatment options were addressed in the context of 
14 drug-company-sponsored symposia, while other symposia on more basic topics 
were organized by investigators either in Milan or at other Italian venues, as well as 
outside Italy (Cracow and Myconos). About 300 oral or poster presenters from various 
countries received travel or accommodations grants to help them to participate in the 
meeting and accumulate experience that may help their future research. Thus the 
meeting continued the traditional success of yearly ESH scientific events. This is a 
good omen for the future meeting which will be held in Madrid in June 2006. 
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HOW TO BECOME A MEMBER OF THE 
 
INTERNATIONAL SOCIETY 
OF HYPERTENSION (ISH) 
 
Applications should be made in writing to the Secretary of the Society,  
Professor Anna F Dominiczak, at the address below, accompanied by a written 
statement from two members of the Society as to the qualifications of the applicant 
plus a list of the five best and the five most recent publications related to hypertension 
or allied fields as well as a short curriculum vitae (CV). 
 
Professor A F Dominiczak 
ISH Secretariat 
Hampton Medical Conferences Ltd.  
113-119 High Street, Hampton Hill   
Middlesex, TW12 1NJ, U.K. 
 
Tel:  +44 (0) 20 8979 8300                     
Fax: +44 (0) 20 8979 6700 
Email: secretariat@ish-world.com  
INTERNATIONAL SOCIETY OF HYPERTENSION 
 
 
A member of the Scientific Advisory Board  
of the World Heart Federation 
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MEMBERSHIP OF THE INTERNATIONAL SOCIETY OF HYPERTENSION (ISH) 
 
APPLICATION FORM  
TITLE         SURNAME     
 
FORENAMES: 
___________________________________________________________________________ 
 
INSTITUTION: 
__________________________________________________________________________ 
 
ADDRESS: 
___________________________________________________________________________ 
 
Telephone No: …………………………………. Fax No: ………………………………………….. 
 
Email: ………………………………………………………………………………… 
__________________________________________________________________________ 
 
NAMES AND ADDRESSES OF TWO ISH MEMBERS WHO SUPPORT THE APPLICATION 
___________________________________________________________________________ 
 
NAME: 
___________________________________________________________________________ 
 
ADDRESS: 
___________________________________________________________________________ 
 
NAME: 
___________________________________________________________________________ 
 
ADDRESS: 
___________________________________________________________________________ 
 
APPLICATIONS SHOULD BE MADE IN WRITING TO THE SECRETARY OF THE SOCIETY, PROFESSOR  
ANNA F DOMINICZAK ACCOMPANIED BY A WRITTEN STATEMENT FROM TWO ISH MEMBERS. 
  
A LIST OF THE FIVE BEST AND THE FIVE MOST RECENT PUBLICATIONS RELATED TO HYPERTENSION OR 
ALLIED FIELDS SHOULD BE ENCLOSED AS WELL AS A SHORT CURRICULUM VITAE (CV). 
 
 
Professor A F Dominiczak 
ISH Secretariat 
Hampton Medical Conferences Ltd.  
113-119 High Street, Hampton Hill   
Middlesex, TW12 1NJ  
U.K. 
 
 
THE ANNUAL ISH MEMBERSHIP FEE AND SUBSCRIPTION TO  
THE JOURNAL OF HYPERTENSION IS CURRENTLY USD 136.50  
 
 
Payment should not be made until membership is approved. Applications for membership will be assessed 
by the Membership Committee and ratified at the next ISH General Business Meeting.  
 
